{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:01:53Z","timestamp":1793282513350,"version":"4.5.0"},"reference-count":85,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Since lipid abnormalities tend to progress from childhood to adulthood, it is necessary to early identify and treat children and adolescents with dyslipidemia. This is important in order to reduce the cardiovascular risk, delay the development of fatty streaks, slow the progression of atherosclerosis and reverse atherosclerotic plaques. Together with therapeutic lifestyle changes, statins are the most common lipid-lowering drugs. By inhibiting the endogenous cholesterol synthesis in the liver, statins increase the catabolism of LDL-C, reduce VLDL-C, IDL-C and TG and modestly increase HDL-C. Regardless of their lipid-lowering effect, statins have also pleiotropic effects. Statins have increasingly been prescribed in children and adolescents and mounting evidence suggests their beneficial role. As with adults, in children, several studies have demonstrated that statin therapy is efficient at lowering lipid levels and reducing CIMT progression and cumulative estimated atherosclerotic burden in children. Statins are generally very well-tolerated in both adults and children and adverse events are quite uncommon. When evaluating the need and the timing for statin treatment, the presence of several factors (secondary causes, familial history, additional risk factors) should also be considered. Before initiating statins, it is imperative for clinical practitioners to consult patients and families and, as with any new medication therapy, to monitor patients taking statins. Despite being safe and effective, many children with lipid disorders are not on statin therapy and are not receiving the full potential benefit of adequate lipid-lowering therapies. It is therefore important that clinicians become familiar with statins.<\/jats:p>","DOI":"10.3390\/ijms24021366","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T02:06:03Z","timestamp":1673402763000},"page":"1366","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Statins in Children, an Update"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1345-0919","authenticated-orcid":false,"given":"Riccardo","family":"Fiorentino","sequence":"first","affiliation":[{"name":"Department of Paediatrics, University of Chieti, Via dei Vestini, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Chiarelli","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Chieti, Via dei Vestini, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"ref_1","unstructured":"Pahwa, R., and Jialal, I. (2021). Atherosclerosis. 2021 Sep 28. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E87","DOI":"10.1093\/eurheartj\/suaa068","article-title":"Subclinical atherosclerosis: How and when to treat it?","volume":"22","author":"Gatto","year":"2020","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-015-0255-y","article-title":"Atherosclerotic cardiovascular disease: A review of initiators and protective factors","volume":"24","author":"Ellulu","year":"2016","journal-title":"Inflammopharmacology"},{"key":"ref_5","unstructured":"Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Hershman, J.M., Hofland, J., and Kalra, S. (2000). The Role of Lipids and Lipoproteins in Atherosclerosis. Endotext [Internet], MDText.com, Inc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.31083\/j.rcm2203088","article-title":"Dyslipidemia in pediatrician\u2019s practice","volume":"22","author":"Burlutskaya","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_7","first-page":"327","article-title":"Assessment of Intima-Media Thickness in Healthy Children Aged 1 to 15 Years","volume":"106","author":"Baroncini","year":"2016","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1089\/met.2017.0149","article-title":"Association Between Carotid Intima Media Thickness, Age, and Cardiovascular Risk Factors in Children and Adolescents","volume":"16","author":"Gooty","year":"2018","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0003319719857384","article-title":"Coronary Intimal Thickening Begins in Fetuses: Proof of Concept for the \u201cFetal Origins of Adult Disease\u201d Hypothesis","volume":"71","author":"Briana","year":"2019","journal-title":"Angiology"},{"key":"ref_10","first-page":"62","article-title":"Coronary Intimal Thickening Begins in Fetuses and Progresses in Pediatric Population and Adolescents to Atherosclerosis","volume":"71","author":"Castilla","year":"2019","journal-title":"Angiology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13052-022-01250-5","article-title":"Cardiovascular risk in children: A burden for future generations","volume":"48","author":"Candelino","year":"2022","journal-title":"Ital. J. Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s10354-018-0626-2","article-title":"Cholesterol metabolism\u2014Physiological regulation and pathophysiological deregulation by the endoplasmic reticulum","volume":"168","author":"Stangl","year":"2018","journal-title":"Wien. Med. Wochenschr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1542\/peds.2006-0970","article-title":"Pathobiological Determinants of Atherosclerosis in Youth Research Group: Pathobiological Determinants of Atherosclerosis in Youth Risk Scores Are Associated with Early and Advanced Atherosclerosis","volume":"118","author":"McMahan","year":"2006","journal-title":"Pediatrics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.cjca.2020.03.041","article-title":"The Rationale, Indications, Safety, and Use of Statins in the Pediatric Population","volume":"36","author":"Khoury","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary","volume":"73","author":"Grundy","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: A report of the american college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4254\/wjh.v4.i6.184","article-title":"Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic \u201cpower station\u201d","volume":"4","author":"Trapani","year":"2012","journal-title":"World J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1021\/acs.biochem.6b00342","article-title":"Cholesterol Biosynthesis: A Mechanistic Overview","volume":"55","author":"Cerqueira","year":"2016","journal-title":"Biochemistry"},{"key":"ref_19","unstructured":"Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Hershman, J.M., Hofland, J., and Kalra, S. (2000). Introduction to Lipids and Lipoproteins. Endotext [Internet], MDText.com, Inc."},{"key":"ref_20","unstructured":"Lent-Schochet, D., and Jialal, I. (2022). Biochemistry, Lipoprotein Metabolism. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCRESAHA.119.312617","article-title":"HDL and Reverse Cholesterol Transport","volume":"124","author":"Ouimet","year":"2019","journal-title":"Circ. Res."},{"key":"ref_22","first-page":"398","article-title":"Statins: Pros and cons","volume":"150","author":"Mammen","year":"2017","journal-title":"Med. Cl\u00ednica (Engl. Ed.)"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(03)00003-5","article-title":"Statin inhibition of HMG-CoA reductase: A 3-dimensional view","volume":"4","author":"Istvan","year":"2003","journal-title":"Atheroscler. Suppl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.pedhc.2019.02.009","article-title":"Clinical Practice Recommendations for Pediatric Dyslipidemia","volume":"33","author":"Elkins","year":"2019","journal-title":"J. Pediatr. Health Care"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"165968","DOI":"10.1016\/j.bbadis.2020.165968","article-title":"Pleiotropic effects of statins: A focus on cancer","volume":"1866","author":"Ahmadi","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.7150\/ijbs.42965","article-title":"Pleiotropic use of Statins as non-lipid-lowering drugs","volume":"16","author":"Zhang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_28","first-page":"CD006401","article-title":"Statins for children with familial hypercholesterolemia","volume":"7","author":"Vuorio","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_29","first-page":"810","article-title":"Statin Treatments and Dosages in Children with Familial Hypercholesterolemia: Meta-Analysis","volume":"111","author":"Radaelli","year":"2018","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12020-020-02302-8","article-title":"Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: A systematic review and meta-analysis of randomized-controlled trials","volume":"69","author":"Anagnostis","year":"2020","journal-title":"Endocrine"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fiorentino, R., and Chiarelli, F. (2021). Treatment of Dyslipidaemia in Children. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091078"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14656566.2020.1832991","article-title":"Rochac Lipid Clinic Heart Institute (Incor), University of S\u00e3o Paulo Medical School Hospital, S\u00e3o Paulo, Brazil; Santos, R.D. Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia","volume":"22","author":"Ferrari","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, and National Heart, Lung, and Blood Institute (2011). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics, 128, S213\u2013S256.","DOI":"10.1542\/peds.2009-2107C"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jacl.2015.06.013","article-title":"Lipid-lowering medications for children and adolescents","volume":"9","author":"Miller","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpeds.2016.08.003","article-title":"Correlates of Achieving Statin Therapy Goals in Children and Adolescents with Dyslipidemia","volume":"178","author":"Mendelson","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The Agenda for Familial Hypercholesterolemia","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.120.046361","article-title":"Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk","volume":"142","author":"Willeit","year":"2020","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and Safety of Statin Therapy in Children with Familial Hypercholesterolemia","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/CIRCULATIONAHA.106.671016","article-title":"Statin Treatment in Children with Familial Hypercholesterolemia","volume":"116","author":"Rodenburg","year":"2007","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/jama.2014.8892","article-title":"Ten-Year Follow-up After Initiation of Statin Therapy in Children with Familial Hypercholesterolemia","volume":"312","author":"Kusters","year":"2014","journal-title":"JAMA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2012.10.032","article-title":"Statin treatment of children with familial hypercholesterolemia\u2014Trying to balance incomplete evidence of long-term safety and clinical accountability: Are we approaching a consensus?","volume":"226","author":"Vuorio","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpeds.2019.03.032","article-title":"Intermediate-Term Efficacy and Tolerance of Statins in Children","volume":"210","author":"Mamann","year":"2019","journal-title":"J. Pediatr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cjco.2020.06.002","article-title":"Effectiveness and Safety of Statin Therapy in Children: A Real-World Clinical Practice Experience","volume":"2","author":"Kavey","year":"2020","journal-title":"CJC Open"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11886-018-1014-7","article-title":"Lipid Screening, Action, and Follow-up in Children and Adolescents","volume":"20","author":"Wiegman","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_48","first-page":"175","article-title":"Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort with Dyslipidemia","volume":"68","author":"Desai","year":"2019","journal-title":"J. Craniofacial Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid-Lowering Arm (ASCOT-LLA): A randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpeds.2017.02.047","article-title":"Statin-Associated Myopathy in a Pediatric Preventive Cardiology Practice","volume":"185","author":"Johnson","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.mcna.2016.06.005","article-title":"Nutrition in Children and Adolescents","volume":"100","author":"Corkins","year":"2016","journal-title":"Med. Clin. N. Am."},{"key":"ref_52","first-page":"160","article-title":"Use of Statins for Dyslipidemia in the Pediatric Population","volume":"15","author":"Eiland","year":"2010","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11883-021-00926-3","article-title":"Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents","volume":"23","author":"Cohen","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2021.05.006","article-title":"Fetal toxicity associated with statins: A systematic review and meta-analysis","volume":"327","author":"Makvandi","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.2174\/1381612824666181010145807","article-title":"Familial Hypercholesterolemia in Children and Adolescents: Diagnosis and Treatment","volume":"24","author":"Maliachova","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/IJGM.S202446","article-title":"Mini-review: Medication safety of red yeast rice products","volume":"12","author":"Farkouh","year":"2019","journal-title":"Int. J. Gen. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3476(03)00186-0","article-title":"Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: A multicenter, randomized, placebo-controlled trial","volume":"143","author":"McCrindle","year":"2003","journal-title":"J. Pediatr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1080\/08035250600702602","article-title":"Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia","volume":"95","author":"Nierman","year":"2006","journal-title":"Acta Paediatr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1542\/peds.97.5.619","article-title":"Treatment of Familial Hypercholesterolemia in Children and Adolescents: Effect of Lovastatin","volume":"97","author":"Lambert","year":"1996","journal-title":"Pediatrics"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.281.2.137","article-title":"Efficacy and Safety of Lovastatin in Adolescent Males with Heterozygous Familial Hypercholesterolemia","volume":"281","author":"Stein","year":"1999","journal-title":"JAMA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1542\/peds.2004-2090","article-title":"Efficacy and Safety of Lovastatin Therapy in Adolescent Girls with Heterozygous Familial Hypercholesterolemia","volume":"116","author":"Clauss","year":"2005","journal-title":"Pediatrics"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpeds.2015.05.006","article-title":"Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk","volume":"167","author":"Braamskamp","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1203\/00006450-199605000-00021","article-title":"Short-Term Efficacy and Safety of Pravastatin in 72 Children with Familial Hypercholesterolemia","volume":"39","author":"Knipscheer","year":"1996","journal-title":"Pediatr. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jacc.2009.10.042","article-title":"Efficacy and Safety of Rosuvastatin Therapy for Children with Familial Hypercholesterolemia","volume":"55","author":"Avis","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.ATV.18.6.1007","article-title":"Association of Specific LDL Receptor Gene Mutations with Differential Plasma Lipoprotein Response to Simvastatin in Young French Canadians with Heterozygous Familial Hypercholesterolemia","volume":"18","author":"Couture","year":"1998","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/01.CIR.0000035247.42888.82","article-title":"Efficacy and Safety of Statin Therapy in Children with Familial Hypercholesterolemia","volume":"106","author":"Ose","year":"2002","journal-title":"Circulation"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","article-title":"National Lipid Association Annual Summary of Clinical Lipidology 2016","volume":"10","author":"Bays","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"ref_68","unstructured":"Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Hershman, J.M., Hofland, J., and Kalra, S. (2000). Use of Lipid Lowering Medications in Youth. Endotext [Internet], MDText.com, Inc."},{"key":"ref_69","first-page":"e603","article-title":"Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement from the American Heart Association","volume":"139","author":"Steinberger","year":"2019","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents (1992). National Cholesterol Education Program (NCEP): Highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics, 89, 495\u2013501.","DOI":"10.1542\/peds.89.3.495"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, and Committee on Nutrition (1998). American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. Pediatrics, 101, 141\u2013147.","DOI":"10.1542\/peds.101.1.141"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1161\/CIRCULATIONAHA.107.181946","article-title":"Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents","volume":"115","author":"McCrindle","year":"2007","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2019.09.005","article-title":"Current management of children and young people with heterozygous familial hypercholesterolaemia\u2014HEART UK statement of care","volume":"290","author":"Ramaswami","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS): The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_75","first-page":"1","article-title":"Homozigot ailevi hiperkolesterolemi: Klinisyenlerin taniyi ve klinik y\u00f6netimi geli\u015ftirmelerine y\u00f6nelik yeni anlayi\u015flar ve rehberlik. Avrupa Ateroskleroz Derne\u011fi\u2019nin Ailevi Hiperkolesterolemi \u00dczerine Uzla\u015fi Paneli yazili g\u00f6r\u00fc\u015f\u00fc [Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]","volume":"43","author":"Cuchel","year":"2015","journal-title":"Turk Kardiyol. Dern. Ars."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e013225","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia","volume":"8","author":"McGowan","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jacl.2017.06.001","article-title":"Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis","volume":"11","author":"Awad","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5223\/pghn.2014.17.2.85","article-title":"Dyslipidemia in Children and Adolescents: When and How to Diagnose and Treat?","volume":"17","author":"Yoon","year":"2014","journal-title":"Pediatr. Gastroenterol. Hepatol. Nutr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11883-020-00881-5","article-title":"Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care","volume":"22","author":"Balla","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1517\/17425255.2015.1056149","article-title":"Drug\u2013drug interactions that interfere with statin metabolism","volume":"11","author":"Hirota","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of Familial Hypercholesterolemia Among the General Population and Patients with Atherosclerotic Cardiovascular Disease","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccl.2015.01.001","article-title":"Familial hypercholesterolemia","volume":"33","author":"Bouhairie","year":"2015","journal-title":"Clin. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2019.11.012","article-title":"Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries","volume":"292","author":"Ramaswami","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_84","first-page":"1","article-title":"Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: A review of the risks and benefits","volume":"7","author":"Conwell","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/VHRM.S266249","article-title":"Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents","volume":"17","author":"Tada","year":"2021","journal-title":"Vasc. Health Risk Manag."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1366\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:52Z","timestamp":1760119552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":85,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24021366"],"URL":"https:\/\/doi.org\/10.3390\/ijms24021366","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}